An update on barriers to adolescent human papillomavirus vaccination in the USA

Expert Review of Vaccines

Volumn 14, Issue 10, 2015, Pages 1377-1384

  Berenson, Abbey B ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

awareness; barriers; cancer prevention; HPV vaccine; human papillomavirus; provider

Indexed keywords

WART VIRUS VACCINE;

AWARENESS; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; PAPILLOMAVIRUS INFECTION; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; UNITED STATES; VACCINATION; WART VIRUS; ADOLESCENT; ATTITUDE TO HEALTH; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONDYLOMATA ACUMINATA; ECONOMICS; FEMALE; IMMUNOLOGY; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PATIENT ATTITUDE; PSYCHOLOGY; SEXUALLY TRANSMITTED DISEASES; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ADOLESCENT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONDYLOMATA ACUMINATA; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PATIENT ACCEPTANCE OF HEALTH CARE; SEXUALLY TRANSMITTED DISEASES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION;

EID: 84941806390     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1078240     Document Type: Review

References (82)

1. Forman D, de MC, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 (Suppl 5): F12-23
2. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63: 1-30
3. Reagan-Steiner S, Yankey D, Jeyarajah D, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years-United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64: 784-92
4. Moss JL, Reiter PL, Brewer NT. Correlates of human papillomavirus vaccine coverage: a state-level analysis. Sex Transm Dis 2015; 42: 71-5
5. Dunne EF, Stokley S, Chen W, Zhou F. Human papillomavirus vaccination of females in a large health claims database in the United States, 2006-2012. J Adolesc Health 2015; 56: 408-13
6. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377: 2085-92
7. Brotherton JM, Saville AM, May CL, et al. Human papillomavirus vaccination is changing the epidemiology of high-grade cervical lesions in Australia. Cancer Causes Control 2015; 26 (6): 953-4
8. Chow EP, Read TR, Wigan R, et al. Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2015; 91: 214-19
9. Pollock KG, Kavanagh K, Potts A, et al. Reduction of low-and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014; 111: 1824-30
10. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep 2014; 63: 620-4
11. Allison MA, Dunne EF, Markowitz LE, et al. HPV vaccination of boys in primary care practices. Acad Pediatr 2013; 13: 466-74
12. Bruno DM, Wilson TE, Gany F, Aragones A. Identifying human papillomavirus vaccination practices among primary care providers of minority, low-income and immigrant patient populations. Vaccine 2014; 32: 4149-54
13. Warner EL, Lai D, Carbajal-Salisbury S, et al. Latino Parents Perceptions of the HPV Vaccine for Sons and Daughters. J Community Health 2015; 40 (3): 387-94
14. CDC vaccine price list. Centers for disease control and prevention, 24 February 2015. Available from: www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html. [Last accessed 25 March 2015]
15. Petrosky E, Bocchini JA Jr, Hariri S, et al. Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 2015; 64: 300-4
16. Malo TL, Hassani D, Staras SA, et al. Do Florida Medicaid providers barriers to HPV vaccination vary based on VFC program participation? Matern Child Health J 2013; 17: 609-15
17. Vadaparampil ST, Murphy D, Rodriguez M, et al. Qualitative responses to a national physician survey on HPV vaccination. Vaccine 2013; 31: 2267-72
18. Luque JS, Tarasenko YN, Dixon BT, et al. Recommendations and administration of the HPV vaccine to 11-to 12-year-old girls and boys: a statewide survey of Georgia vaccines for children provider practices. J Low Genit Tract Dis 2014; 18: 298-303
19. Vadaparampil ST, Staras SA, Malo TL, et al. Provider factors associated with disparities in human papillomavirus vaccination among low-income 9-to 17-year-old girls. Cancer 2013; 119: 621-8
20. Reiter PL, Gupta K, Brewer NT, et al. Provider-verified HPV vaccine coverage among a national sample of Hispanic adolescent females. Cancer Epidemiol Biomarkers Prev 2014; 23: 742-54
21. Cowburn S, Carlson M, Lapidus J, et al. Insurance continuity and human papillomavirus vaccine uptake in Oregon and California federally qualified health centers. Am J Public Health 2014; 104: e71-9
22. Harper DM, Verdenius I, Harris GD, et al. The influence of free quadrivalent human papillomavirus vaccine (HPV4) on the timely completion of the three dose series. Prev Med 2014; 61: 20-5
23. Reiter PL, McRee AL, Pepper JK, et al. Longitudinal predictors of human papillomavirus vaccination among a national sample of adolescent males. Am J Public Health 2013; 103: 1419-27
24. Dorell C, Yankey D, Kennedy A, Stokley S. Factors that influence parental vaccination decisions for adolescents, 13 to 17 years old: National Immunization Survey-Teen, 2010. Clin Pediatr (Phila) 2013; 52: 162-70
25. Kester LM, Zimet GD, Fortenberry JD, et al. A national study of HPV vaccination of adolescent girls: rates, predictors, and reasons for non-vaccination. Matern Child Health J 2013; 17: 879-85
26. Perkins RB, Apte G, Marquez C, et al. Factors affecting human papillomavirus vaccine use among White, Black and Latino parents of sons. Pediatr Infect Dis J 2013; 32: e38-44
27. Reiter PL, Brewer NT, Gilkey MB, et al. Early adoption of the human papillomavirus vaccine among Hispanic adolescent males in the United States. Cancer 2014; 120: 3200-7
28. Reiter PL, Katz ML, Paskett ED. Correlates of HPV vaccination among adolescent females from Appalachia and reasons why their parents do not intend to vaccinate. Vaccine 2013; 31: 3121-5
29. Gerend MA, Zapata C, Reyes E. Predictors of human papillomavirus vaccination among daughters of low-income Latina mothers: the role of acculturation. J Adolesc Health 2013; 53: 623-9
30. Wilson R, Brown DR, Boothe MA, Harris CE. Knowledge and acceptability of the HPV vaccine among ethnically diverse black women. J Immigr Minor Health 2013; 15: 747-57
31. Gargano LM, Herbert NL, Painter JE, et al. Impact of a physician recommendation and parental immunization attitudes on receipt or intention to receive adolescent vaccines. Hum Vaccin Immunother 2013; 9: 2627-33
32. Polonijo AN, Carpiano RM. Social inequalities in adolescent human papillomavirus (HPV) vaccination: a test of fundamental cause theory. Soc Sci Med 2013; 82: 115-25
33. Taylor VM, Burke NJ, Ko LK, et al. Understanding HPV vaccine uptake among Cambodian American girls. J Community Health 2014; 39: 857-62
34. Darden PM, Thompson DM, Roberts JR, et al. Reasons for not vaccinating adolescents: National immunization survey of teens, 2008-2010. Pediatrics 2013; 131: 645-51
35. Perkins RB, Clark JA, Apte G, et al. Missed opportunities for HPV vaccination in adolescent girls: a qualitative study. Pediatrics 2014; 134: e666-74
36. Malo TL, Giuliano AR, Kahn JA, et al. Physicians human papillomavirus vaccine recommendations in the context of permissive guidelines for male patients: a national study. Cancer Epidemiol Biomarkers Prev 2014; 23: 2126-35
37. McRee AL, Gilkey MB, Dempsey AF. HPV vaccine hesitancy: findings from a statewide survey of health care providers. J Pediatr Health Care 2014; 28: 541-9
38. Bynum SA, Staras SA, Malo TL, et al. Factors associated With Medicaid providers recommendation of the HPV vaccine to low-income adolescent girls. J Adolesc Health 2014; 54: 190-6
39. Perkins RB, Anderson BL, Gorin SS, Schulkin JA. Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists. Am J Prev Med 2013; 45: 175-81
40. Roberts JR, Thompson D, Rogacki B, et al. Vaccine hesitancy among parents of adolescents and its association with vaccine uptake. Vaccine 2015; 33 (14): 1748-55
41. Healy CM, Montesinos DP, Middleman AB. Parent and provider perspectives on immunization: are providers overestimating parental concerns? Vaccine 2014; 32: 579-84
42. Ylitalo KR, Lee H, Mehta NK. Health care provider recommendation, human papillomavirus vaccination, and race/ethnicity in the US National Immunization Survey. Am J Public Health 2013; 103: 164-9
43. Perkins RB, Lin M, Silliman RA, et al. Why are u.s. Girls getting meningococcal but not human papilloma virus vaccines? Comparison of factors associated with human papilloma virus and meningococcal vaccination among adolescent girls 2008 to 2012. Womens Health Issues 2015; 25: 97-104
44. Kepka D, Warner EL, Kinney AY, et al. Low human papillomavirus (HPV) vaccine knowledge among Latino parents in Utah. J Immigr Minor Health 2015; 17: 125-31
45. Gold R, Naleway A, Riedlinger K. Factors predicting completion of the human papillomavirus vaccine series. J Adolesc Health 2013; 52: 427-32
46. Buchwald D, Muller C, Bell M, Schmidt-Grimminger D. Attitudes toward HPV vaccination among rural American Indian women and urban White women in the northern plains. Health Educ Behav 2013; 40: 704-11
47. New survey data from planned parenthood and the center for Latino adolescent and family health shows parents need more information about the HPV vaccine. Planned Parenthood Federation of America, 2015. Available from: www.plannedparenthood.org/about-us/newsroom/press-releases/new-survey-data-from-planned-parenthood-and-the-center-for-latino-adolescent-and-family-health-shows-parents-need-more-informati. [Last accessed 26 March 2015]
48. Davlin SL, Berenson AB, Rahman M. Correlates of HPV knowledge among low-income minority mothers with a child 9-17 years of age. J Pediatr Adolesc Gynecol 2015; 28: 19-23
49. Barnack-Tavlaris JL, Garcini LM, Macera CA, et al. Human Papillomavirus Vaccination Awareness and Acceptability Among U.S.-Born and U.S. Foreign-Born Women Living in California. Health Care Women Int 2014; 1-19
50. Blake KD, Ottenbacher AJ, Finney Rutten LJ, et al. Predictors of human papillomavirus awareness and knowledge in 2013: Gaps and opportunities for targeted communication strategies. Am J Prev Med 2015; 48 (4): 402-10
51. Morales-Campos DY, Markham CM, Peskin MF, Fernandez ME. Hispanic mothers and high school girls perceptions of cervical cancer, human papilloma virus, and the human papilloma virus vaccine. J Adolesc Health 2013; 52: S69-75
52. Miller MK, Wickliffe J, Jahnke S, et al. Views on human papillomavirus vaccination: a mixed-methods study of urban youth. J Community Health 2014; 39: 835-41
53. Gutierrez B Jr, Leung A, Jones KT, et al. Acceptability of the human papillomavirus vaccine among urban adolescent males. Am J Mens Health 2013; 7: 27-36
54. Fernandez ME, Le YC, Fernandez-Espada N, et al. Knowledge, attitudes, and beliefs about human papillomavirus (HPV) vaccination among Puerto Rican mothers and daughters, 2010: a qualitative study. Prev Chronic Dis 2014; 11: E212
55. Hull PC, Williams EA, Khabele D, et al. HPV vaccine use among African American girls: qualitative formative research using a participatory social marketing approach. Gynecol Oncol 2014; 132 (Suppl 1): S13-20
56. Dorell C, Yankey D, Jeyarajah J, et al. Delay and refusal of human papillomavirus vaccine for girls. national immunization survey-teen, 2010. Clin Pediatr (Phila) 2014; 53: 261-9
57. Jena AB, Goldman DP, Seabury SA. Incidence of Sexually Transmitted Infections After Human Papillomavirus Vaccination Among Adolescent Females. JAMA Intern Med 2015; 175 (4): 617-23
58. Mayer MK, Reiter PL, Zucker RA, Brewer NT. Parents and sons beliefs in sexual disinhibition after human papillomavirus vaccination. Sex Transm Dis 2013; 40: 822-8
59. Blackman E, Thurman N, Halliday D, et al. Multicenter study of human papillomavirus and the human papillomavirus vaccine: knowledge and attitudes among people of African descent. Infect Dis Obstet Gynecol 2013; 2013: 428582
60. Schuler CL, Hanley CJ, Coyne-Beasley T. Misconception: human papillomavirus vaccine and infertility. Clin Pediatr (Phila) 2014; 53: 158-65
61. Gardasil-EPAR summary for the public. European medicines agency, 4 August 2014. Available from: www.ema.europa.eu/docs/enGB/documentlibrary/EPARSummaryforthepublic/human/000703/WC500021146.pdfa. [Last accessed 13 July 2015]
62. World Health Organization. Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations. Vaccine 2014. [Epub ahead of print]
63. Tsai Y, Zhou F, Wortley P, et al. Trends and characteristics of preventive care visits among commercially insured adolescents, 2003-2010. J Pediatr 2014; 164: 625-30
64. Parra-Medina D, Morales-Campos DY, Mojica C, Ramirez AG. Promotora Outreach, Education and Navigation Support for HPV Vaccination to Hispanic Women with Unvaccinated Daughters. J Cancer Educ 2014; 30 (2): 353-9
65. Dempsey AF, Mendez D. Examining future adolescent human papillomavirus vaccine uptake, with and without a school mandate. J Adolesc Health 2010; 47: 242-8. 248
66. You are the key to cancer prevention (Online Presentation). Centers for disease control and prevention, 2015. Available from: www.cdc.gov/vaccines/who/teens/for-hcp/hpv-resources.html. [Last accessed 9 April 2015]
67. Vanderpool RC, Crosby RA, Stradtman LR. Protecting a new generation against HPV: are we willing to be bold? Hum Vaccin Immunother 2014; 10: 2559-61
68. Yi JK, Lackey SC, Zahn MP, et al. Human papillomavirus knowledge and awareness among Vietnamese mothers. J Community Health 2013; 38: 1003-9
69. Strohl AE, Mendoza G, Ghant MS, et al. Barriers to prevention: knowledge of HPV, cervical cancer, and HPV vaccinations among African American women. Am J Obstet Gynecol 2015; 212: 65
70. Hofstetter AM, Rosenthal SL. Factors impacting HPV vaccination: lessons for health care professionals. Expert Rev Vaccines 2014; 13: 1013-26
71. Sinka K, Kavanagh K, Gordon R, et al. Achieving high and equitable coverage of adolescent HPV vaccine in Scotland. J Epidemiol Community Health 2014; 68: 57-63
72. Binagwaho A, Ngabo F, Wagner CM, et al. Integration of comprehensive womens health programmes into health systems: cervical cancer prevention, care and control in Rwanda. Bull World Health Organ 2013; 91: 697-703
73. Nodulman JA, Starling R, Kong AS, et al. Investigating stakeholder attitudes and opinions on school-based human papillomavirus vaccination programs. J Sch Health 2015; 85: 289-98
74. Building on opportunities in cancer research. National Cancer Institute, National institutes of health 2015. Available from: www.cancer.gov/aboutnci/budgetplanningleg/plan-archives/NCIs-Annual-Plan-Budget-Proposal-Fiscal-Year-2016.pdf. [Last accessed 9 April 2015]
75. Lazcano-Ponce E, Stanley M, Munoz N, et al. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs a three-dose schedule at 21 months. Vaccine 2014; 32: 725-32
76. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309: 1793-802
77. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011; 7: 1374-86
78. October 16, 2009 Approval letter-Cervarix. FDA, 2012. Available from: www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186959.htm. [Last accessed 16 April 2015]
79. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907
80. June 8, 2006 Approval letter-Human papillomavirus quadrivalent (Types 6, 11, 16, 18) Vaccine, Recombinant. FDA, 2009. Available from: www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm111283.htm. [Last accessed 16 April 2015]
81. October 16, 2009 Approval letter-Gardasil. FDA, 2009. Available from: www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm186991.htm. [Last accessed 16 April 2015]
82. December 10, 2014 Approval letter-Gardasil 9. FDA, 2014. Available from: www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm426520.htm. [Last accessed 16 April 2015]